Three to six year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor

被引:149
作者
Cavallaro, AM
Lilleby, K
Majolino, I
Storb, R
Appelbaum, FR
Rowley, SD
Bensinger, WI [1 ]
机构
[1] Univ Washington, Fred Hutchinson Canc Ctr, Seattle, WA 98195 USA
[2] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[3] Osped V Cervello, Div Ematol, Unita Trapianti, Palermo, Italy
关键词
G-CSF; filgrastim; normal donors; allogeneic stem cells;
D O I
10.1038/sj.bmt.1702072
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
One hundred and one donors who had received filgrastim (rhG-CSF) for the purpose of donating either granulocytes or peripheral blood stem cells (PBSC) for their relatives more than 3 years ago were contacted. All donors had received daily rhG-CSF at a median dose of 16 mu g/kg/day (range 3-16) for a median of 6 days (range 3-15 days). All collection procedures were completed and short-term side-effects of rhG-CSF were mild in the majority of the donors. At a median time interval of 43.13 months (range 35-73), the donors were contacted to assess whether adverse effects related to rhG-CSF administration had occurred. Prior to rhG-CSF two donors had cancer, one had a myocardial infarction, one was hepatitis C virus positive, one had a history of sinusitis, one had Graves' disease and two had arterial hypertension, None worsened with the rhG-CSF administration but the donor with a history of infarction had an episode of angina following apheresis, and the donor with Graves' disease had a stroke 15 months after rhG-CSF, Two pregnancies occurred after the rhG-CSF administration and one donor was 2-3 weeks pregnant during rhG-CSF treatment. Three pregnancies resulted in two normal births and one in a spontaneous abortion of a pregnancy which occurred more than 2 years following rhG-CSF, In the time following rhG-CSF administration two donors developed cancer (breast and prostate cancer) at a follow-up of 70 and 11 months, respectively. One donor developed lymphadenopathy 38 months after the rhG-CSF, which spontaneously resolved. Blood counts were obtained in 70 donors at a median follow up of 40.4 months (range 16.8-70.8). Hematocrit was 43% (median, range 36.8-48), white blood cells were 5.7 x 10(9)/l (median, range 3-14), granulocytes 3.71 x 10(9)/l (median, range 1.47-10.36), lymphocytes 1.67 x 10(9)/l (median, range 0.90-3.96), monocytes 0.46 x 10(9)/l (median, range 0.07-0.87) and platelet counts were 193.0 x 10(9)/l (median, range 175.0-240.0). This study indicates that short-term administration of rhG-CSF to normal donors for the purpose of mobilizing the PBSC or granulocytes appears safe and without any obvious adverse effects more than 3 years after the donation.
引用
收藏
页码:85 / 89
页数:5
相关论文
共 33 条
  • [1] Anderlini P, 1997, BLOOD, V90, P903
  • [2] Clinical toxicity and laboratory effects of granulocyte-colony-stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures
    Anderlini, P
    Przepiorka, D
    Seong, D
    Miller, P
    Sundberg, J
    Lichtiger, B
    Norfleet, F
    Chan, KW
    Champlin, R
    Korbling, M
    [J]. TRANSFUSION, 1996, 36 (07) : 590 - 595
  • [3] AVALOS BR, 1990, BLOOD, V75, P851
  • [4] Becker P S, 1997, Biol Blood Marrow Transplant, V3, P45
  • [5] THE EFFECTS OF DAILY RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR ADMINISTRATION ON NORMAL GRANULOCYTE DONORS UNDERGOING LEUKAPHERESIS
    BENSINGER, WI
    PRICE, TH
    DALE, DC
    APPELBAUM, FR
    CLIFT, R
    LILLEBY, K
    WILLIAMS, B
    STORB, R
    THOMAS, ED
    BUCKNER, CD
    [J]. BLOOD, 1993, 81 (07) : 1883 - 1888
  • [6] BENSINGER WI, 1992, MARROW TRANSPLANTATION : PRACTICAL AND TECHNICAL ASPECTS OF STEM CELL RECONSTITUTION, P157
  • [7] BORTIN MM, 1983, EXP HEMATOL, V11, P916
  • [8] BUCKNER CD, 1984, BLOOD, V64, P630
  • [9] DREGER P, 1993, BLOOD, V81, P1404
  • [10] Falanga A., 1996, Bone Marrow Transplantation, V17, pS72